Pramlintide
Pramlintide is a relatively new adjunct treatment for diabetes (both type 1 and 2), developed by Amylin Pharmaceuticals. It is derived from amylin, a hormone that is released into the bloodstream, in a similar pattern as insulin, after a meal. Like insulin, amylin is deficient in individuals with diabetes.
| Trivial name | Pramlintide |
| Catalog Number | TP-007CL |
| Alternative Name(s) | Pramlintide |
| Research Area | Endocrine disorders (hormone deficiencies) |
| Molecular Formula | C171H267N51O53S2 |
| CAS# | 151126-32-8 |
| Purity | >90% |
| Size | 1 mg |
| Supplier Page | https://www.creativebiolabs.net/Pramlintide-22345.htm |
| Additional Information | For the treatment of type 1 and type 2 diabetes mellitus as an adjunct to preprandial insulin therapy in patients without adequate glycemic control of insulin therapy. |